GSK, IDRx

GSK to buy US biotech firm IDRx for up to $1.15 billion
(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx,
GSK to buy Boston-based IDRx for $1.15 billion
GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement signed by both companies,
GSK Enters Agreement to Acquire IDRx, Inc.
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.
GSK confirms plan to buy cancer firm IDRx for $1bn
This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, with another $150 million in payments to the biotech's shareholders if its pipeline delivered as expected.
GSK to acquire IDRx for $1B upfront
GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B
GSK CEO on acquisition of biotech firm IDRx
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
Is GSK prepping a $1bn takeover bid for IDRx?
GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST).
GSK to buy rare cancer drug developer IDRx for up to £1bn
Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million in 'success-based' milestone payments.
GSK to buy cancer-focused IDRx in $1 billion deal
Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront.
FierceBiotech2d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
BioSpace1d
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
ENDPOINTS NEWS1d
GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
BioPharma Dive7h
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning
Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended that Keytruda's coming loss of ...
GSK To Acquire GIST Drug Developer IDRx For Up To $1.15 Bln Cash
(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...